Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Edwards Lifesciences
January 13, 2023

Medtech approvals stagnate

Device approvals hit a nine-year low in 2022, as the FDA takes its foot further off the gas.

Thumbnail
November 18, 2022

Big medtechs’ efficiency starts to recover from Covid

Orthopaedics and cardiology groups start to improve in terms of sales per employee, but Covid test makers do better still.

Article image
Vantage logo
September 20, 2022

TCT 2022 – Edwards tries to Clasp an opportunity

The Pascal valve repair device boasts a pivotal hit and US approval, but can it compete?

Article image
Vantage logo
November 19, 2021

Covid-19 takes its toll on medtechs’ efficiency

Staffing levels changed little across 2020 as M&A slowed – but sales are another story.

Article image
Vantage logo
November 08, 2021

TCT 2021 – Medtronic and Edwards target hard-to-reach valves

Transcatheter technologies could be the future – but a distant one.

Article image
Vantage logo
August 05, 2021

Keystone hopes approval slots into place

Article image
Vantage logo
May 18, 2021

Aortic opportunity remains narrow for Abbott

Abbott’s latest aortic valve launch is unlikely to gain it a meaningful slice of the market; meanwhile, Edwards’ attention has switched to tricuspid.

Article image
Vantage logo
March 30, 2021

Medtronic builds on its pulmonary legacy

Article image
Vantage logo
February 24, 2021

Medtech’s haves and have-nots

Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.

Article image
Vantage logo
November 17, 2020

Boston deadheads its Lotus

Beset with problems from the off, the Lotus Edge aortic valve has finally been discontinued.

Article image
Vantage logo
September 03, 2020

Medtechs that book the most sales per employee face the greatest losses

Welcome to the calm before the Covid-19 storm.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up